More pharma brands are investing time and money into digital HCP engagement programs than ever. But something they need to understand is that more digital touchpoints don't automatically mean more attention from medical professionals. If you have more ways to reach clinicians today, they also have more ways to find information. They're also expecting information that's relevant, useful, and worth their time.
That throws a wrench into your marketing team’s playbook. The goal isn't to add another email, portal, or webinar to the mix. It's to understand what an HCP is trying to do, respond to that signal, and make each interaction useful enough to keep the conversation moving.
This article breaks down what effective digital HCP engagement looks like and the strategies pharma teams can use to make those interactions more relevant and effective.
We can sum it up to three major factors that have disrupted the traditional model of HCP engagement in pharma. Physical (or in-person) access has become harder, clinicians are no longer searching for answers through the same sources or channels, and finally, commercial teams have realized that spamming more emails does nothing to earn more attention. These changes have made the old channel-by-channel approach less effective.
The healthcare sector has been adding more and stricter compliance requirements over the years that have reduced the number of pharma representatives legally allowed to visit physicians in each territory. It so happens that the number of physicians willing to see a rep has dropped significantly as well.
Clinical workloads add another challenge. HCPs have no time to sit through scheduled meetings with pharma representatives.
When a pharma company's entire reach strategy is based on field access, they end up meeting whoever happens to be free on a given day, rather than those who they actually wanted to meet. This is why HCP engagement is moving to digital channels for pharma brands, as they make it easier to deliver relevant information without relying on whether a physician has time for an in-person meeting.
Times have changed. HCPs no longer wait for pharmaceutical companies to send sales representatives over to deliver answers. They instead rely on their professional social networks or follow medical publishers. Following the push for AI tools, most HCPs simply ask LLMs to answer clinical questions.
That digital shift has completely changed what engagement means. A McKinsey survey revealed that 60% of HCPs prefer to access information from pharmaceutical companies through multiple channels rather than relying on a single relationship with a specific sales representative.
In this context, speed matters more than ever. A medical professional searching between appointments won't wait for a pharma rep to call. They'll always take whatever source answers first, which is rarely pharma brands these days.
Adding more sales reps isn't the answer many pharma brands might expect. On paper, expanding the field team could seem like a way to make up for lost access, but in reality, it doesn't solve the root problem of delivering fast, relevant content to HCPs.
Research from EPG Health found that 77% of pharma respondents consider providing real value a challenge in digital HCP engagement. A physician who's receiving more emails than ever is also finding less and less relevant content. Hence, HCPs are being pushed toward third-party or independent sources they trust, which makes it harder for another promotional email to stand out in a crowded inbox.
That is the reality a modern HCP digital engagement strategy has to address. The goal isn't simply to reach HCPs more often. It's to give them a reason to engage when you do.
Take note that each engagement channel below earns its place for a different reason. Don't think of it as a list of strategies to add to an existing plan. Each one runs differently than the next, so it's worth knowing what each start is actually good for.
Despite how both are often used freely, a corporate email is very different from a rep's. An email from a pharma representative lands with the weight of an existing professional relationship. A corporate email, though, feels like just another message from a brand.
It's why pharma reps have an average open rate of around 35%, compared with just 3% for emails sent from corporate HQs.
The difference lies in how the rep gives the email a reason to be opened. The physician knows they can start a conversation after the email, have their questions answered, or share relevant material. Corporate emails don't have that one-to-one context. They feel less personalized and more like something sent to a dozen other HCPs that day.
Phone calls and text messages are highly effective for the small moments (or routine interactions) most pharma companies don't strategize around. For example, a quick appointment confirmation or coordinating with the clinical staff responsible for screening information before it reaches a physician.
The ability of these channels to reach their recipients quickly, with high read rates, is why teams choose them first.
Consent becomes a problem here though. Both voice and text carry strict opt-in requirements. Teams can't just call HCPs at random, so a digital engagement program that doesn't account for those requirements is destined to fail.
This shouldn't even be debatable. Platforms like Doximity, Medscape, and other medical journals have credibility that a pharma company's own channels can never compete with. For HCPs, the same clinical content on a medical platform reflects a different level of trust than when sent from a pharma email. The gap here is that those platforms aren't selling anything, but the pharma companies are.
Online meetings with a pharma sales representative or MSL offer unique value that other channels struggle to match. This is primarily because they can hold a complex clinical discussion, ensuring HCPs actually get the information they need in real time.
Even more interesting is how a remote HCP meeting typically runs for around 14 minutes, more than twice the length of a physical meeting.
That extra time doesn't mean an HCP needs to commit to a longer meeting. A remote meeting can be scheduled without the travel, office logistics, and other coordination involved in getting a representative into a practice. An HCP who needs five minutes to get an answer can use those five minutes without having to make room for a full in-person visit.
Not all HCPs engage with content the same way. Some prefer live sessions for real-time Q&As, while others tend to watch recordings on their own time. Any engagement strategy that's built for one HCP segment loses the other by design.
Additionally, follow-ups are just as important. Someone who attended a live session has already shown interest. Their next interaction should build on what they heard in that webinar, for example. However, someone who registered but never attended hasn't had that same experience and shouldn't receive the same follow-up.
Livestorm's research found that 57% of registrants attend webinars on average, making the post-event journey an important part of any HCP digital engagement strategy.
Pharmas don't always make the first move. Sometimes it's the HCP that reaches out first. Maybe they want to request a sample or have a reimbursement question. This makes engagement all the more important because the HCP has already made their specific need clear.
But many programs still treat these interactions as simple service requests. So a pharma rep will answer the questions and mark the interaction closed, leaving behind a valuable signal that could be used to build further engagement.
Every HCP digital engagement program needs to account for the constraints faced by most pharmaceutical marketing teams. You can't just assume a perfect scenario. There are always going to be missing physician data, limited manpower and time. The strategies mentioned below do exactly that, basing themselves on the reality of the pharma sector.
Segmentation is nothing new. Most teams group their HCPs by specialty, region, and prescribing volume. But that doesn't really tell you how an HCP wants to hear from you. Their engagement behavior is what opens the door for you. Do they prefer checking emails or require a physical rep? Maybe they want a mix of both.
Gather and use that behavioral data (at least 90 days) to build your groups. Then monitor whether that segmentation needs further updates, because behavioral changes are common. For instance, a physician might have relied mainly on sales representatives last quarter, but they could shift to digital channels following a new product launch.
Pharmaceutical marketing teams revolve their content around building a brand. However, clinicians don't care for that much. All they want is their questions answered. So they'll only read your content if it actually contains those answers.
For example, tools like dosing calculators and patient selection checklists are more likely to capture an HCP's attention than a mere slide containing efficacy data.
That's the main difference between pharmaceutical engagement content that actually gets opened and read, and content that is ignored immediately after the email subject line is seen.
The whole point of 'not' spamming HCPs with emails is that they become accustomed to completely ignoring everything from you. Now consider a pharma company that's using five different channels to send the same message. That's never a sound HCP engagement strategy. If a physician has ignored your email and field visit, they're likely to ignore your webinar invite as well.
Using an adaptive sequence produces better results because the next engagement step is based on what happened just now. Say a healthcare professional opened your email but didn't click through. Don't send them the same email again. Instead, follow up with something shorter with one link. Maybe they click through this time and remain engaged on the page for a short time. The next step would then be to have your rep call them and reference the content they were just reading. The point is that non-response should change your next move.
It's common for marketing campaign calendars to dictate how and when outreach happens. But, again, that approach doesn't account for the HCP's actual situation.
Consider a physician who just prescribed a drug to a patient. They'd never be interested in meeting a that drug's competitor a day later. Similarly, why would someone be interested in attending a webinar when they've already attended a similar session last week?
These are signals or events that pharma companies need to use for their outreach. Look for behavior signals such as content downloads or repeat visits to a resource page, clinical signals like a new drug addition in an HCP's region, or market signals like a competitor's label update. Any of these can start an interaction or stop one.
Something else many teams do is log separate records for inbound and outbound communications. That adds another layer of thoroughness, which might seem important, but it mostly causes a rep to meet an HCP without knowing they actually asked something last week through a completely different channel.
That email the physician sent to request information, or the form they filled out? Keep them in the same HCP record.
Now, most teams avoid doing this because many questions start to feel like support tickets. The trick is resolving the routine inquiries via a knowledge base or scripted response, and routing the complex ones to your main pharma specialists.
If a physician views a webpage regarding safety monitoring, that information should be reflected in the pharma rep's briefing before their next visit. This is important because it allows the conversation to start from the physician's interest rather than relying on a generic sales pitch.
Similarly, if a representative learns during a visit that a physician has adjusted their patient profile, the cadence of digital outreach should be adapted accordingly. That's what makes it a two-way flow between field operations and digital signals.
Personalization helps any HCP digital engagement strategy, but it also hits your MLR capacity by creating new content versions. Each one is more work for your review team to approve, and it multiplies further as every personalized interaction creates more combinations.
A modular approach caps the approval cycle. Teams approve the building blocks instead of a complete asset for every possible use. For example, a safety statement or dosing table can be defined once and then reused without going through the entire asset again.
The same principle can apply to common content combinations. Pre-clear the variants you know reps and digital channels will use most often, so personalization happens within an approved framework rather than starting another MLR cycle every time.
Compliance isn't something your legal team reviews after launching a digital HCP program. It's part of the design process as the program is being built from the ground up. Take due note. Any pharmaceutical company that leaves compliance until the end often ends up reworking their engagement programs anyway.
Just because an HCP is interacting with a chatbot instead of a human doesn't change the fair balance rule. If the chatbot shares efficacy data with a physician, it also needs to share the associated risk information.
The same goes for claims. A statement about a drug's safety or use needs to lead back to an approved label or a credible source, or else the HCP is going to disengage.
AI makes the review process harder because the tool isn't limited to one approved response. Someone can ask the same question twice and get two different answers. In regulated industries like healthcare and pharma, even a small change in wording can change the meaning of a statement. That means reviewing one script isn't enough. Your marketing team needs to test a range of likely responses and make sure each one stays accurate and compliant.
The safest starting point is to keep the model grounded in approved content rather than letting it pull from whatever information it can find. Responses that touch on an unapproved indication should also be caught and stopped before they reach the HCP.
Gathering contact details for HCPs is only one step. You still need to know how you can use them because HCP digital engagement strategies rely on permission that's specific to the channel as well as the jurisdiction.
Someone who agreed to receive emails hasn't necessarily agreed to receive texts, just as consent given in one country doesn't automatically carry over to another.
A medical license doesn't create an exception, either. Sending a text to an HCP's mobile number can still put the interaction under the TCPA in the US.
So document consent the moment you get it. Record when it was given, which channel it covers, and where it came from so there's a clear trail if regulators ever ask for it.
A digital interaction can create value more often than teams expect. That could be a virtual meal delivered to an HCP during a webinar, or travel and lodging tied to a hybrid event. The format of the engagement doesn't necessarily change the reporting obligation.
The US Open Payments law dictates that companies should have a record of what was provided, to whom, and when. Trying to reconstruct that information weeks later from expense reports and event records leaves plenty of room for compliance gaps. So it makes more sense to capture the information as the interaction happens.
There was a time when promotional and medical interactions could sit much closer together. That doesn't work as well under today's compliance expectations. When both teams work inside the same CRM, the platform needs safeguards that keep their information and access properly separated.
That starts with who can see what. A commercial team member shouldn't have access to unpublished medical affairs insights, just as an MSL shouldn't be able to see sales targets tied to a specific HCP. Role-based permissions can enforce those boundaries without forcing both teams onto completely separate systems.
You also need to know when those boundaries are crossed. Keep an audit trail showing who accessed specific content and when. That gives compliance teams a record they can review if questions arise about how medical or commercial information was handled.
Everything we've discussed so far revolves around finding what piques the HCP's interest. Hence, metrics like open rates and click-throughs are only good enough to reflect their behavior. You still need metrics that track their actions following the initial touchpoint.
Start by tracking the time spent per session, as well as whether they return within a month or two. A physician that follows up even on the 90th day signals interest.
For long-form content, it's essential to track drop-off points. If your data says that HCPs from a specific specialty left a webinar within the first 15 minutes, your content team knows exactly where to make cuts.
Furthermore, tie engagement data to follow-up actions. This is something most pharma companies water down. Sample requests and meeting appointments hold more value than page views, while inquiries regarding formularies are even more critical, as they reflect intent that is extremely close to a prescribing decision.
Finally, and most importantly, actually take action on what you find. Don't just log it in a report that won't get read until the next quarterly meeting. Digital engagement programs that know the difference between "effective" and "ineffective" formats smartly reallocate resources.
Maybe a specialist group is losing interest in long-form content, but at the same time is showing interest in short videos. In this case, the budget should be shifted toward that group's preferred format before the start of the next quarter.
A pharma marketing campaign typically means sending the same content or message to a list of HCPs and then tracking how many clicked through. A journey-engagement approach works differently. It focuses on what those HCPs are actually doing and adjusts the next interaction accordingly.
That shift changes how your teams collect, connect, and use engagement data. So HCP digital channels only earn their keep for pharma brands when that data feeds into one system that compliance can check, and commercial teams can actually run.
Every HCP should have only one record in your system to run a coordinated journey. That profile, so to speak, must collect the following data:
A decisioning layer typically sits over all your channels and systems to decide what the next-best action is before execution.
By giving them complete visibility into what all the other channels are doing, the system can more accurately decide which HCP to contact next and through which channel. This also gives the brand one place to see the full picture of pharma HCP engagement across every touchpoint.
What it does not decide is how the information is formatted or the sequence of delivery. Those specific operational details remain the responsibility of the individual channel tools.
Pharmaceutical brands that try to integrate every channel and cover all HCP segments most often stall before launch. Unifying data alone can take months, and stakeholders often lose patience when they do not see tangible deliverables from the system.
What actually works is narrowing your approach. Pick one journey, such as an HCP onboarding process following the approval of a new drug, and then define clear success criteria. Is your goal to achieve more sample requests, or to convince more HCPs to approve a rep meeting?
Run that journey to the end to see if you achieve the desired action results. Adapt as needed before scaling to add more journeys. This approach allows you to validate the ROI of HCP engagement months before a full rollout.
While data and decision-making address the technical aspects of coordinated journeys, ownership is an organizational issue. It's also something most pharma engagement programs overlook.
Contact conflict is the most obvious sign of a lack of clear ownership. For instance, a sales representative might plan to visit an HCP during a specific week, while the marketing department simultaneously schedules an email to that same HCP. At the same time, the medical affairs team may also need to contact the HCP to discuss a clinical case.
Without a designated lead to coordinate these conflicts, pharma teams risk either overwhelming HCPs with excessive contact, or everyone backs off and nothing goes out at all.
HCP engagement gets harder when you're supporting multiple channels and all of them are running on their own. Your next marketing campaign might account for field data, but not what your emails are saying. WestCX brings those interactions into a fully connected journey, giving pharmaceutical companies an easier way to coordinate outreach across commercial teams, patient services, MSLs, and Medical Affairs from one system. The engagement history of each HCP follows them regardless of who engages with them next and through which channel.
That coordination, however, is only useful when your teams can actually act on the context behind each interaction. That's where WestCX Orchestrate™ comes in, adding a decision-making layer that connects those signals and helps determine the next-best action based on what an HCP has done, where they are in their journey, and what they need next.
So instead of treating every interaction as a new campaign, pharma teams can use context to guide the next interaction across the right channel.
That might sound like something that requires a complete overhaul of your existing systems, but it’s not. As an engagement solution for pharma, WestCX Orchestrate integrates with your existing tech stack without requiring you to replace it.
If your teams are stretched trying to connect and scale HCP engagement programs, schedule a demo to see how WestCX Orchestrate can help coordinate every interaction and guide the next-best action.